MRNA Additional Paid-in Capital History: $1.38B (FY2025)

Fiscal year	Q1	Q2	Q3	Q4
FY26	$1.5B+53.1%	Not reported	Not reported	Not reported
FY25	$982M+101.6%	$1.1B+78.6%	$1.3B+67.0%	$1.4B+59.6%
FY24	$487M−33.4%	$631M+226.9%	$751M+171.1%	$866M+133.4%
FY23	$731M−79.9%	$193M−92.0%	$277M−81.4%	$371M−68.4%
FY22	$3.6B−25.0%	$2.4B−51.1%	$1.5B−70.3%	$1.2B−72.1%

01—History

Additional Paid-in Capital History

Year-over-year comparison from 10-K annual reports · Dashed line: constant growth FY2020–FY2025. Drag across the bars to change the range.

$1.38B

YoY changeLargest recent move+133.4%in FY24Latest +59.6%

1 older move runs past ±150% (largest +3441.0%); point at, tap or drag across the bars to read one.

02—Ledger

Additional Paid-in Capital, period by period

Period	Value	Change	Source
FY2025	$1.38B	+59.6%	10-K
FY2024	$866.0M	+133.4%	10-K
FY2023	$371.0M	−68.4%	10-K
FY2022	$1.17B	−72.1%	10-K
FY2021	$4.21B	−12.3%	10-K
FY2020	$4.80B	+79.9%	10-K
FY2019	$2.67B	+5.2%	10-K
FY2018	$2.54B	+3441.0%	10-K
FY2017	$71.7M	—	10-K

03—Questions

What is Moderna, Inc.'s current additional paid-in capital?

Moderna, Inc. (MRNA) annual additional paid-in capital for 2025 was $1.38B, a 59.58% increase from 2024. Moderna, Inc. additional paid-in capital for the quarter ending March 31, 2026 was $1.50B.

What was Moderna, Inc.'s additional paid-in capital in 2024?

Moderna, Inc. annual additional paid-in capital for 2024 was $866.0M, a 133.42% increase from 2023.

What was Moderna, Inc.'s additional paid-in capital in 2023?

Moderna, Inc. annual additional paid-in capital for 2023 was $371.0M, a 68.37% decline from 2022.

What is Moderna, Inc.'s 5-year additional paid-in capital CAGR?

Moderna, Inc. additional paid-in capital grew at a compound annual growth rate (CAGR) of 22.05% from FY2020 to FY2025, going from $4.80B to $1.38B over 5 years.

Company: Moderna, Inc.
Ticker: MRNA
Sector: Healthcare
Industry: Biological Products, (No Diagnostic Substances)

Moderna, Inc. Additional Paid-in Capital 2017-2026 | MRNA

Key Statistics